For example, it has been shown that targeting RSK2 with specific inhibitors or small interfering RNAs remarkably inhibits the growth and renewal of tumor-initiating cells in triple-negative breast cancer (TNBC) and that RSK2 promotes migration through the ERK/MEK pathway (Stratford et al., 2012). Here, MAP2K7 is linked to triple-negative breast carcinoma.